Correlation Between Kronos Bio and InMed Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Kronos Bio and InMed Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kronos Bio and InMed Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kronos Bio and InMed Pharmaceuticals, you can compare the effects of market volatilities on Kronos Bio and InMed Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kronos Bio with a short position of InMed Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kronos Bio and InMed Pharmaceuticals.

Diversification Opportunities for Kronos Bio and InMed Pharmaceuticals

0.39

Correlation Coefficient

Kronos Bio  InMed Pharmaceuticals

Weak diversification

The 3 months correlation between Kronos and InMed is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Kronos Bio and InMed Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on InMed Pharmaceuticals and Kronos Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kronos Bio are associated (or correlated) with InMed Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of InMed Pharmaceuticals has no effect on the direction of Kronos Bio i.e., Kronos Bio and InMed Pharmaceuticals go up and down completely randomly.

Pair Corralation between Kronos Bio and InMed Pharmaceuticals

Given the investment horizon of 90 days Kronos Bio is expected to generate 0.47 times more return on investment than InMed Pharmaceuticals. However, Kronos Bio is 2.12 times less risky than InMed Pharmaceuticals. It trades about -0.04 of its potential returns per unit of risk. InMed Pharmaceuticals is currently generating about -0.17 per unit of risk. If you would invest  92.00  in Kronos Bio on December 26, 2024 and sell it today you would lose (5.81) from holding Kronos Bio or give up 6.32% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Kronos Bio  vs.  InMed Pharmaceuticals

Kronos Bio

Risk-Adjusted Performance

Very Weak

Over the last 90 days Kronos Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Kronos Bio is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

InMed Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days InMed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Kronos Bio and InMed Pharmaceuticals

The main advantage of trading using opposite Kronos Bio and InMed Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kronos Bio position performs unexpectedly, InMed Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InMed Pharmaceuticals will offset losses from the drop in InMed Pharmaceuticals' long position.

The idea behind Kronos Bio and InMed Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.